Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
arGEN-X BV - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'arGEN-X BV - Product Pipeline Review - 2016', provides an overview of the arGEN-X BV's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by arGEN-X BV, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of arGEN-X BV - The report provides overview of arGEN-X BV including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses arGEN-X BV's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features arGEN-X BV's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate arGEN-X BV's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for arGEN-X BV - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding arGEN-X BV's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 arGEN-X BV Snapshot 5 arGEN-X BV Overview 5 Key Information 5 Key Facts 5 arGEN-X BV - Research and Development Overview 6 Key Therapeutic Areas 6 arGEN-X BV - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Pipeline Products - Out-Licensed Products 13 Out-Licensed Products/Combination Treatment Modalities 14 arGEN-X BV - Pipeline Products Glance 15 arGEN-X BV - Clinical Stage Pipeline Products 15 Phase I Products/Combination Treatment Modalities 15 arGEN-X BV - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 Discovery Products/Combination Treatment Modalities 17 arGEN-X BV - Drug Profiles 18 ARGX-110 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 ARGX-111 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 ARGX-113 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 ARGX-112 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 ARGX-115 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Monoclonal Antibodies for Cancer, Immunology and Metabolic Disorders 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Monoclonal Antibody for Skin Inflammation 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Monoclonal Antibodies to Block Nav1.7 for Chronic Pain 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 arGEN-X BV - Pipeline Analysis 31 arGEN-X BV - Pipeline Products by Target 31 arGEN-X BV - Pipeline Products by Route of Administration 32 arGEN-X BV - Pipeline Products by Molecule Type 33 arGEN-X BV - Pipeline Products by Mechanism of Action 34 arGEN-X BV - Recent Pipeline Updates 35 arGEN-X BV - Dormant Projects 39 arGEN-X BV - Locations And Subsidiaries 40 Head Office 40 Other Locations & Subsidiaries 40 Appendix 41 Methodology 41 Coverage 41 Secondary Research 41 Primary Research 41 Expert Panel Validation 41 Contact Us 41 Disclaimer 42
List of Tables
arGEN-X BV, Key Information 5 arGEN-X BV, Key Facts 5 arGEN-X BV - Pipeline by Indication, 2016 7 arGEN-X BV - Pipeline by Stage of Development, 2016 9 arGEN-X BV - Monotherapy Products in Pipeline, 2016 10 arGEN-X BV - Partnered Products in Pipeline, 2016 11 arGEN-X BV - Partnered Products/ Combination Treatment Modalities, 2016 12 arGEN-X BV - Out-Licensed Products in Pipeline, 2016 13 arGEN-X BV - Out-Licensed Products/ Combination Treatment Modalities, 2016 14 arGEN-X BV - Phase I, 2016 15 arGEN-X BV - Preclinical, 2016 16 arGEN-X BV - Discovery, 2016 17 arGEN-X BV - Pipeline by Target, 2016 31 arGEN-X BV - Pipeline by Route of Administration, 2016 32 arGEN-X BV - Pipeline by Molecule Type, 2016 33 arGEN-X BV - Pipeline Products by Mechanism of Action, 2016 34 arGEN-X BV - Recent Pipeline Updates, 2016 35 arGEN-X BV - Dormant Developmental Projects,2016 39 arGEN-X BV, Subsidiaries 40
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.